SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-007745
Filing Date
2019-08-08
Accepted
2019-08-08 17:01:22
Documents
77
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20190630x10q.htm 10-Q 2580737
2 EX-31.1 acrs-20190630ex311b7f958.htm EX-31.1 17140
3 EX-31.2 acrs-20190630ex312ce1a6c.htm EX-31.2 17126
4 EX-32.1 acrs-20190630ex3212ed7ab.htm EX-32.1 10662
  Complete submission text file 0001558370-19-007745.txt   9928474

Data Files

Seq Description Document Type Size
5 EX-101.INS acrs-20190630.xml EX-101.INS 2489019
6 EX-101.SCH acrs-20190630.xsd EX-101.SCH 51154
7 EX-101.CAL acrs-20190630_cal.xml EX-101.CAL 60988
8 EX-101.DEF acrs-20190630_def.xml EX-101.DEF 182622
9 EX-101.LAB acrs-20190630_lab.xml EX-101.LAB 554039
10 EX-101.PRE acrs-20190630_pre.xml EX-101.PRE 378030
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 191010426
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences